期刊文献+

腹腔注射阿霉素诱导实验扩张型心肌病大鼠模型的建立 被引量:6

The dilated cardiomyopathy model in rat induced intraperitoneal injection of adriamycin
下载PDF
导出
摘要 目的建立稳定可靠的扩张型心肌病(DCM)动物模型,以供基础实验研究。方法选用雄性SD大鼠,分为正常对照组和DCM模型组,DCM组予腹腔注射阿霉素2.5mg/(kg.week),生理盐水稀释浓度为1mg/ml,正常组腹腔注射等量生理盐水。每周根据体重调整阿霉素剂量,用药6周后,检查心脏超声、血浆脑钠肽(BNP)水平、观察心肌病理切片。结果心脏超声心动图示模型组左室射血分数(LVEF)、左室短轴缩短率(FS),各项指标明显低于正常对照组(P<0.01)。模型组大鼠血浆BNP水平高于正常对照组(P<0.01)。心肌病理HE染色观察、结果符合DCM改变。结论该制造扩张型心肌病动物模型的方法成功率高,造模周期较短,结果可靠,可以做为基础研究的动物模型。 Objective Establish a stable and reliable dilated cardiomyopathy(DCM) animal models for basic experimental research.Methods Male SD rats were divided into normal group and DCM group in random.intraperitoneal injection of doxorubicin to the DCM group(2.5 mg/(kg·week)),Diluted with normal saline concentration of 1mg/ml,Intraperitoneal injection of saline to the normal group.Weekly doxorubicin dose adjustments based on body weight,medication after 6 weeks,assess echocardiography,plasma brain natriuretic peptide(BNP) levels,myocardial biopsy.Results The DCM group left ventricular ejection fraction(LVEF),left ventricular fractional shortening(FS),the index was significantly lower than the normal group(P0.01),plasma BNP levels higher than the normal group(P0.01).Myocardial HE staining,results in line with DCM pathology.Conclusion The means of dilated cardiomyopathy animal model a high success rate,short-cycle modeling,reliable,can be used as animal models for basic research.
出处 《中国实验诊断学》 2012年第12期2185-2187,共3页 Chinese Journal of Laboratory Diagnosis
基金 上海市卫生局中医药科研基金(2012L021A)
关键词 阿霉素 扩张型心肌病 Adriamycin DCM
  • 相关文献

参考文献10

二级参考文献76

  • 1黄荣杰,刘唐威,伍伟锋,庞玉生.呋喃唑酮制备大鼠扩张型心肌病模型[J].中国病理生理杂志,2005,21(11):2147-2150. 被引量:28
  • 2杨英珍,陈瑞珍.扩张型心肌病发病机制和治疗的研究新动向[J].中华心血管病杂志,2006,34(3):196-197. 被引量:47
  • 3白洁,陈蓉,盛佳,汪健飞,张国辉.SD大鼠扩张型心肌病模型的建立[J].江苏大学学报(医学版),2006,16(3):210-212. 被引量:14
  • 4Richardson P, Mckenna W, Bfistow M, et al. Report of the 1995 world health organization/international society and federation of cardiolgy task force on the definition and classification of cardiomyopathies[J]. Circulation, 1996, 93 : 841 - 842.
  • 5MaronBJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies [ J ]. Circulation, 2006, 113 : 1807- 1816.
  • 6Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in framingham Heart study subjects [ J]. Circulation, 1993, 88: 107-115.
  • 7Kamisago M, Sharma SD, Depalma SR, et al. Mutations in sareomere protein genes as a cause of dilated cardiomyopathy [J]. N Engl J Med, 2000, 343:1688-1696.
  • 8Chang AN, Potter JD. Sareomeric protein mutations in dilated eardiomyopathy [J]. Heart Fail Rev, 2005, 10:225- 235.
  • 9ViUard E, Duboscq-Bido L, Charron P, et al. Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene [J]. Eur Heart J, 2005, 26:794 - 803.
  • 10Jiang QS, Huang XN, Yang GZ, et al. Inhibitory effect of ginsenoside Rbl on calcineurin signal pathway in cardiomyocyte hypertrophy induced by prostaglandin F2alpha[J].Acta Pharmacol Sinica, 2007, 28 : 1149 - 1154.

共引文献185

同被引文献33

  • 1MCNAMARA D M,STARLING R C,COOPER L T, et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy results of the IMAC (Intervention in Myocarditis and Acute Cardio- myopathy)-2 study[J]. J Am Coil Cardiol, 2011,58 : 1112-1118.
  • 2WANG Y G, HILL J. Electrophysiological remodeling in heart failure [J]. J Mol Cell Cardiol, 2010,48 : 619 - 632.
  • 3SWARTZ M F, FINK G W, LUTZ C J, et al. Left versus right atrial differencein dominant frequency, K channel transcripts, and fibrosis in patients developing atrial fibrillation after cardiac surgery I-J]. Heart Rhythm, 2009,6 : 1 415- 1422.
  • 4KONCZ I, GURABI Z, PATOCSKAI B,et al. Mech- anisms underlying the development of the electrocar- diographic and arrhythmic manifestations of early re- polarization syndrome [J].J Mol Cell Cardiol, 2014 , 68:20-28.
  • 5MAOZ A, KROGH-MADSEN T, CHRISTIN1 D J. Instability in action potential morphology underlies phase 2 reentry: a mathematical modeling study [J]. Heart Rhythm, 2009,6 (8) : 813 - 822.
  • 6Ferrans VJ, Clark JR, Zhang J, et al. Pathogenesis and prevention ofdoxorubicin cardiomyopathy[J]. Tsitologiia, 1997, 39(10): 928-937.
  • 7Vandecruys E, Mondelaers V, De Wolf D, et al. Late cardiotoxicityafter low dose of anthracycline therapy for acute lymphoblasticleukemia in childhood[J]. J Cancer Surviv, 2012, 6(1): 95-101.
  • 8Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associatedrisk for acute myeloid leukemia/myelodysplastic syndrome and othersecondary malignancies in pediatric Hodgkin's disease[J]. J ClinOncol, 2007, 25(5): 493-500.
  • 9Seif AE, Walker DM, Li Y, et al. Dexrazoxane exposure and risk ofsecondary acute myeloid leukemia in pediatric oncology patients[J] .Pediatr Blood Cancer, 2015, 62(4): 704-709.
  • 10Hrdina R, Gersl V, Klimtova I, et al. Anthracycline-inducedcardiotoxicity[J]. Acta medica, 2000, 43(3): 75-82.

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部